Thrombosis and cancer: Retrospective study of 17 cases

Background: The association cancer and venous thrombosis is almost always an independent criterion of poor prognosis of cancer. Thus, venous thromboembolic disease is with infection and organ failure, one of the leading causes of death in patients with malignant disease. Aim: To identify the characteristics of the association between cancer and venous thrombosis in any patient with deep vein thrombosis of lower limbs seemingly unexplained. Methods: This is a retrospective study from January 1994 to December 2008, concerning 17 cases of patients with deep vein thrombosis of lower limbs associated with neoplasia, hospitalized in internal medicine department at Habib Thameur hospital between a total of 290 patients with deep vein thrombosis of lower limbs. Only patients hospitalized for deep vein thrombosis of lower limbs complicated or not by a pulmonary embolism were included. Results: Our study concerned 17 patients. There were 10 women and 7 men with a sex ratio (Female / Male) at 1, 42. The average age was 68.7 years, with extreme ages ranging from 40 to 90 years. Cancer has formed 6% of the causes of deep venous thrombosis of lower limbs. Eight of our patients were known to suffer from a cancerous disease. Six cases of cancers were discovered at an advanced stage of evolution with multiple metastases. In seven cases the etiological could not be achieved. Deep venous thrombosis was complicated by pulmonary embolism in four inaugural events, five patients had recurrent thrombosis, and two cases of bleeding complications were noted. Conclusion: Venous thromboembolism is common in cancer patients. It can be the first manifestation of cancer completely silent. The course and prognosis depend on the stage of cancer combined.     

Thrombosis and cardiovascular disease.

It was only quite recently that the thrombotic component in myocardial infarction and sudden coronary death was generally acknowledged. When attention was eventually paid to it, interest initially centered primarily on platelet function. There is, of course, no doubt about the central role of platelet adhesion and aggregation in thrombogenesis, but still no generally accepted measure of platelet function has been shown to be associated with the later onset of ischemic heart disease (IHD). Epidemiologically, the assessment of coagulability has been more rewarding. Several prospective studies have now shown a strong relationship between the plasma fibrinogen level and the incidence of IHD and stroke. Epidemiologic and laboratory studies have also implicated factor VII and extrinsic pathway activity in the onset of IHD. Other components of the hemostatic system that are probably involved include factor VIII activity and the fibrinolytic system. It is increasingly clear that lipoproteins exert a major influence on coagulability as well as their better known role in atherogenesis. Any further polarization of hypotheses for IHD as being purely atherogenic or purely thrombogenic is therefore counterproductive. At the same time, antithrombotic measures for primary prevention need to be evaluated as thoroughly as lipid-lowering regimens. If thrombosis is seen as the final arterial event in virtually all major episodes of IHD, the indications for antithrombotic agents in primary prevention may be wider than those for lipid-lowering regimens. It is therefore necessary to establish as quickly as possible not only the preventive effectiveness of antithrombotic measures, including low-dose aspirin and low-intensity oral anticoagulation, but also the relative effectiveness and safety of antithrombotic and lipid-modifying regimens.     

罕见PICC继发性异位致深静脉血栓合并颅内静脉窦血栓形成

本文报告了1例因经外周静脉置入中心静脉导管（PICC）继发性异位致深静脉血栓合并颅内静脉窦血栓的罕见病例,通过积极正确救治,患者痊愈出院的原因分析,研究探讨如何规避及减少或者及早发现发生PICC继发性异位所致深静脉血栓合并颅内静脉窦血栓形成,以及一旦发生后并发症的治疗及护理对策。     

Platelets in Thrombosis: Mechanisms and Therapy

With greater knowledge of the processes involved in platelet aggregation, it has become clear that these are important not only in thrombus formation but also in inflammatory and immunologic reactions. The therapeutic implications may be far-reaching: Certain drugs have already been shown to inhibit the release of platelet constituents following aggregation in response to injury.     

Platelets and Thrombosis in Acute Myocardial Infarction

By initiating and then sustaining the thrombotic process without involving the mechanisms of blood clotting, platelet aggregation plays a significant, if not yet fully defined, role in atherosclerosis and its complications. This finding suggests a new focus in therapy: the use of agents that inhibit platelet function (of which several are available) in preference to those that primarily affect coagulation.     

血栓形成机制及抗凝药物的药理特点

血栓形成即血液的局部凝结,可发生在动脉或静脉循环中,它是缺血性心脏病、缺血性脑卒中和静脉血栓栓塞症( venous thromboembolism,VTE)的共同病理基础.缺血性心脏病和中风占全球死亡人数的四分之一[1] ,已成为人类死亡的首要病因.深静脉血栓和肺栓塞统称VTE,是继心梗和卒中后第3位的心血管相关性疾病...